NEW YORK: According to a report by Global Market Insights, Inc., the Biotechnology Market size will exceed USD 775.2 billion with 9.9% CAGR from 2016 to 2024. Based on technology, the industry is segmented into tissue engineering and regeneration, fermentation, PCR, nanobiotechnology, chromatography, DNA sequencing, and more.
In recent years, the tissue engineering and regeneration segment accounted for highest revenue and was valued at over USD 104.5 billion. However, the nanobiotechnology, fermentation and cell based assay segments will experience strong growth thanks to rising R&D investments by various biotechnological and pharmaceutical companies. Cosmos Holdings Inc. (OTC: COSM), Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), CASI Pharmaceuticals, Inc. (NASDAQ: CASI), Protalix BioTherapeutics, Inc. (NYSE: PLX), Infinity Pharmaceuticals, Inc. (NASDAQ: INFI)
The global cancer immunotherapy market by itself is expected to reach USD 118.8 billion by 2025 according to Grand View Research Inc. The market is expected to benefit from introduction of newer drug classes, such as target receptors for multiple myeloma and checkpoint inhibitors. "Increase in number of approvals for new immunotherapeutic drugs is driving the global market. Introduction of new molecules has been proving to be beneficial for patients who are not responding to chemotherapy. Several new immunotherapeutic options, such as immunomodulators and CAR-T cell therapy, are in the pipeline and are being tested for their ability to provide better cancer treatment," Grand View Research indicates.
Cosmos Holdings Inc. (OTCQB: COSM) announced on November 16th that, "it has entered into a $3 million securities purchase agreement with two institutional investors. "We are excited to announce the addition of two institutional investors," said Grigorios Siokas, President and CEO of Cosmos Holdings. "This agreement will provide us with capital to continue to grow our operations and expand our business."
The securities sold have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This release is not used for the purpose of conditioning the market in the United States for any of the securities offered."
About Cosmos Holdings, Inc. - Cosmos Holdings Inc. is a pharmaceutical company focused on identifying, acquiring, developing, and commercializing medicines to improve patients' lives and outcomes. The Company has a trans-European network of over 110 clients and vendors expands to 16 countries including: Germany, United Kingdom, Ireland, United Arab Emirates, Denmark, Italy, France, Singapore, Spain, Lebanon, Skopje, Jordan, Sweden, Poland, Netherlands, and AN or circumstances occurring after the date hereof or the occurrence of unanticipated events or for any changes or modifications made to this press release or the information contained herein by any third-parties, including, but not limited to, any wire or internet services.
